Hematology / Oncology
ABP 654 is an investigational biosimilar to STELARA® (ustekinumab). It is a monoclonal antibody that inhibits
IL-12 and IL-23.
ABP 938 is an investigational biosimilar to EYLEA® (aflibercept). It is a vascular endothelial growth factor receptor (VEGFR) Fc fusion protein.
ABP 959 is an investigational biosimilar to SOLIRIS® (eculizumab). It is a monoclonal antibody that specifically binds to the complement protein C5.
STELARA is a trademark of Janssen Biotech, Inc.
EYLEA is a trademark of Regeneron Pharmaceuticals, Inc.
SOLIRIS is a trademark of Alexion Pharmaceuticals, Inc.